Market research
SCP.F Scancell Holdings plc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 84M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.69
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00B63D3314
- Market cap
- 84M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.69
About
About Scancell Holdings plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SCP.F discussion.
5 years, 5 months ago
Scancell Holdings plc is currently in a long term uptrend where the price is trading 23.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 0.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 31.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Scancell Holdings plc gets an overall score of 2/5.